S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:DNLI

Denali Therapeutics Stock Forecast, Price & News

$73.03
-0.96 (-1.30 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$69.50
Now: $73.03
$74.31
50-Day Range
$60.97
MA: $77.92
$93.56
52-Week Range
$12.39
Now: $73.03
$93.94
Volume31,178 shs
Average Volume828,510 shs
Market Capitalization$8.76 billion
P/E RatioN/A
Dividend YieldN/A
Beta2
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Denali Therapeutics logo

MarketRank

Overall MarketRank

1.11 out of 5 stars

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548
Employees281

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.68 million
Book Value$4.11 per share

Profitability

Net Income$-197,610,000.00
Net Margins-968.59%

Miscellaneous

Market Cap$8.76 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$73.03
-0.96 (-1.30 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

How has Denali Therapeutics' stock price been impacted by Coronavirus?

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DNLI stock has increased by 332.6% and is now trading at $73.03.
View which stocks have been most impacted by COVID-19
.

Is Denali Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Denali Therapeutics?

Wall Street analysts have given Denali Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Denali Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Denali Therapeutics
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks' consensus estimate of $4.19 by $4.73. The company had revenue of $9.39 million for the quarter, compared to the consensus estimate of $564.69 million. Denali Therapeutics had a negative return on equity of 39.19% and a negative net margin of 968.59%.
View Denali Therapeutics' earnings history
.

What price target have analysts set for DNLI?

12 brokers have issued 12-month price targets for Denali Therapeutics' stock. Their forecasts range from $20.00 to $100.00. On average, they anticipate Denali Therapeutics' stock price to reach $51.20 in the next year. This suggests that the stock has a possible downside of 29.9%.
View analysts' price targets for Denali Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Denali Therapeutics' key competitors?

What other stocks do shareholders of Denali Therapeutics own?

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO & Director (Age 44, Pay $887.99k)
  • Dr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 47, Pay $611.86k)
  • Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 60, Pay $55k)
  • Mr. Steve E. Krognes, CFO & Treasurer (Age 52, Pay $665.91k)
  • Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 47, Pay $624.8k)
  • Mr. Tyler M. Nielsen, VP of Corp. Fin. (Age 42)
  • Dr. Dana Andersen, Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock, Chief Scientific Officer
  • Dr. Laura Hansen, VP of Investor Relations
  • Mr. Chris Walsh, Associate Gen. Counsel

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bellecapital International Ltd. (0.01%) and Patriot Financial Group Insurance Agency LLC (0.00%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts and Steve E Krognes.
View institutional ownership trends for Denali Therapeutics
.

Which major investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Bellecapital International Ltd., and Patriot Financial Group Insurance Agency LLC. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, and Steve E Krognes.
View insider buying and selling activity for Denali Therapeutics
or view top insider-selling stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $73.03.

How big of a company is Denali Therapeutics?

Denali Therapeutics has a market capitalization of $8.76 billion and generates $26.68 million in revenue each year. The company earns $-197,610,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Denali Therapeutics employs 281 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is www.denalitherapeutics.com.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.